Page 8 - Scientific Library
How is Amylo-Glo a brighter, longer lasting and higher definition Amyloid plaque marker?
In a previous post I discussed 3 new unique research tools for analyzing Amyloid peptide in Alzheimer’s Disease (AD). Today, I'd like to come back to the unique properties of the Amylo-Glo® fluorescent
Bioactive small molecule sourcing - when quality meets expectations
Bioactive small molecules facilitate numerous types of Life Science research approaches (enzyme substrates, activators and inhibitors, cell signaling modulator, cell culture...). Accessing reasonably
Celastrol inhibits NF-kB pathway in Multiple Myeloma
Celastrol is a biologically active substance initially described in the traditional Chinese medicine. Celastrol (or (9ß,13α,14ß,20α)-3-Hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic
IP3-mediated STIM1 oligomerization requires intact mitochondrial Ca2+ uptake by Deak et al.
Deak AT et al. decipher the mechanisms by which mitochondria contribute to Ca2+ intracellular signaling. In their recent paper (1), they show that mitochondrial "Ca2+ buffering" close to the Endoplasmic
Adipokines in obesity and glucose homeostasis
Obesity is the abnormal increase in adipose tissue mass. This phenomenon increases the likelyhood of a number of diseases such as heart disease, high blood pressure, type 2 diabetes, obstructive sleep
Immunogenicity in biotherapeutics and biosimilars
Following on from my previous post on biosimilars and biotherapeutics (or biologics), let's now take a look at some of the specific criteria for this kind of compound, which are not normally required
Proteasome inhibitor approved by FDA for Myeloma retreatment
The U.S. Food and Drug Administration (FDA) has approved Velcade (Bortezomib) for the retreatment of adult patients with Multiple Myeloma who had previously responded to Velcade therapy and relapsed